Provide anytime, anywhere access to evidence-based approaches, like cognitive behavioral therapy, fluency training, and contingency management, with the clinically proven prescription digital therapeutic that meets their needs.1,2
*During the last 4 weeks of trial.
*During 12 weeks of treatment.
Patients can record substance use, cravings, and triggers to make in-person or remote therapy more productive and meaningful.2
Interactive cognitive behavioral therapy lessons help patients learn new skills they can use in everyday situations to support their recovery journey.2
Questions at the end of each lesson help patients remember important ideas and practice skills to stay in treatment.2
Make use of reSET’s available contingency management capabilities to provide patients with tangible rewards, like accomplishment badges and gift cards, to reinforce positive, healthier behaviors.2
Rewards may be virtual (nonmonetary) or in the form of gift cards (possibly ranging in amounts different from those shown here) and are at the discretion of the prescriber.
*During 12 weeks of treatment. Those who didn’t add reSET-O received treatment as usual.
For individuals with opioid use disorder, reSET-O® is the only FDA-authorized prescription digital therapeutic that’s proven to help patients stay in treatment longer.1,4 It works in a way that meets patients where they already are, on their smartphones, so they can turn screen time into therapy time. Patients prescribed reSET-O download it to their phone for secure, discreet, and convenient access to therapy, interactive learning, and support.
Patients can record substance use, cravings, and triggers to make in-person or remote therapy more productive and meaningful.1
Patients can set up daily reminders to take their medication.1
Interactive cognitive behavioral therapy lessons help patients learn new skills they can use in everyday situations to support their recovery journey.1
Questions at the end of each lesson help patients remember important ideas and practice skills to stay in treatment.1
Make use of reSET-O’s available contingency management capabilities to provide patients with tangible rewards, like accomplishment badges and gift cards, to reinforce positive, healthier behaviors.1
Rewards may be virtual (nonmonetary) or in the form of gift cards (possibly ranging in amounts different from those shown here) and are at the discretion of the prescriber.
Hear from HCPs and patients as they talk about the ways reSET-O and reSET are helping them stay connected, accountable and fully engaged in recovery.
The PearConnect™ Service Center is all about helping you and your patients stay focused on treatment and recovery. Start here for flexible prescribing options, downloadable forms, tech assistance and more.
reSET® Indications for Use:
reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.
It is intended to:
reSET® Important Safety Information for Clinicians:
Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).
Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.
reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.
The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.
The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.
Please see the Clinician Brief Summary Instructions for reSET.
reSET-O® Indications for Use:
reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.
reSET-O® Important Safety Information for Patients:
Warnings/precautions: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).
Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.
reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.
The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.
Please see the Clinician Brief Summary Instructions for reSET-O.
References:
1. reSET-O Clinician directions for use. Pear Therapeutics, Inc. 2020.
2. reSET Clinician directions for use. Pear Therapeutics, Inc. 2020.
3. FDA permits marketing of mobile medical application for substance use disorder. News Release. Silver Spring, MD: US Food and Drug Administration. September 14, 2017. Accessed May 18, 2020. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-mobile-medical-application-substance-use-disorder
4. FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs. News release. Silver Spring, MD: US Food and Drug Administration. December 10, 2018. Accessed May 18, 2020. https://www.fda.gov/news-events/press-announcements/fda-clears-mobile-medical-app-help-those-opioid-use-disorder-stay-recovery-programs
Watch the video to see how reSET and reSET-O can support the recovery journey.
This past year saw a devastating 30% increase in overdose deaths, the highest annual jump and the highest total ever recorded.1
September is National Recovery Month, and Pear is committed to supplying access to treatment—anytime, anywhere. Our Prescription Digital Therapeutics (PDTs), reSET® and reSET-O®, provide treatment for substance use disorder (SUD) and opioid use disorder (OUD), as well as support for those ready to continue their recovery journeys.*
Connect with us to learn more about how reSET and reSET-O can support your patients and your practice. Get Started*SUD and OUD are chronic conditions, and permanent recovery is uncertain. reSET and reSET-O may help to retain patients in treatment.
Reference: 1. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. Updated August 1, 2021.
https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.